Product Overview
MyPath Melanoma was validated in cutaneous melanocytic lesions to accurately differentiate between benign and malignant melanocytic lesions of unknown potential, based on the expression of 23 genes using standard quantitative qRT-PCR that provides an accurate and objective classification suggestive of benign, intermediate, or malignant.
MyPath Melanoma has demonstrated reproducible results across 10 publications including validation to dermatopathology experts' diagnoses and outcomes.
DiffDx-Melanoma has demonstrated high levels of both sensitivity and specificity with a low rate of intermediate results across a wide range of melanocytic subtypes and high rate of technical success.
Order MyPath® Melanoma
Video Webinar
An introduction to our diagnostic GEP by Castle Biosciences Medical Director Matthew Goldberg, MD.
Quick Links
Expert Opinions in Melanoma
When Is the MyPath Melanoma Test Most Helpful
On-Demand
Educational Programs
